Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + dalotuzumab + pemetrexed
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The combination of cisplatin, dalotuzumab, and pemetrexed is an investigational treatment regimen primarily studied for non-small cell lung cancer (NSCLC), particularly non-squamous NSCLC. This combination brings together three distinct agents with complementary mechanisms of action. Dalotuzumab (MK-0646) is a humanized IgG1 monoclonal antibody targeting the Insulin-like Growth Factor 1 Receptor (IGF-1R), aiming to block proliferation and survival signals. Pemetrexed is an antifolate antineoplastic agent disrupting folate-dependent metabolic processes, approved for NSCLC and malignant pleural mesothelioma. Cisplatin is a platinum-based chemotherapy commonly used with pemetrexed in NSCLC. A randomized phase II trial investigating this combination as first-line therapy for non-squamous lung cancer was initiated but closed prematurely due to a sponsoring company's decision and dalotuzumab's overall failure to demonstrate sufficient efficacy in clinical development.
- Other names
- pemetrexedcisplatindalotuzumab
02
Targets
DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)IGF-1R (Insulin-like growth factor 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on cisplatin + dalotuzumab + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + dalotuzumab + pemetrexed.